What is uMotif?
Established in 2012 and headquartered in London, uMotif provides a robust, patient-centered data capture platform designed to streamline modern research workflows. The company addresses the growing demand for high-quality, real-time patient data in clinical studies, offering a digital interface that enhances participant engagement and data integrity. By bridging the gap between traditional research methodologies and digital-first patient experiences, uMotif enables pharmaceutical and biotechnology firms to accelerate their development timelines while maintaining rigorous scientific standards. Its platform is engineered to support complex study designs, ensuring that researchers can capture actionable insights directly from the patient's perspective in a secure and compliant environment.
How much funding has uMotif raised?
uMotif has raised a total of $25.5M across 1 funding round:
Private Equity
$25.5M
Private Equity (2022): $25.5M with participation from Athyrium Capital Management
Key Investors in uMotif
Athyrium Capital Management
Athyrium Capital Management is a leading investment management platform focused on structured investments in the global healthcare sector, providing financing solutions that support growth objectives for pharmaceutical and biotechnology companies.
What's next for uMotif?
With this major enterprise-level funding, uMotif is poised to scale its operations and expand its footprint within the global life sciences sector. The strategic allocation of this capital will likely focus on enhancing the platform's analytical capabilities, integrating advanced machine learning for data validation, and broadening its reach into new therapeutic areas. As the industry shifts toward more patient-centric research models, uMotif is well-positioned to capitalize on the increasing demand for digital health solutions that improve trial efficiency and patient retention. Future growth will likely involve deepening partnerships with global research organizations and further refining its technology to meet the evolving regulatory requirements of international clinical research.
See full uMotif company page
